TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17678651

Group type: EXPERIMENTAL
Intervention: Vaginal estradiol supplementation (E(2) 2 mg twice a day starting on the day of ET)
Number of subjects: 166

Group type: COMPARATOR
Intervention: No E(2) supplementation (control group)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Vaginal estradiol supplementation (E(2) 2 mg twice a day starting on the day of ET) in long GnRH agonist suppression protocol
Number of subjects: 166

Group type: COMPARATOR
Intervention: No E(2) supplementation (control group) in long GnRH agonist suppression protocol
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Vaginal estradiol supplementation (E(2) 2 mg twice a day starting on the day of ET) in GnRH antagonist or microdose GnRH agonist protocols
Number of subjects: 166

Group type: COMPARATOR
Intervention: No E(2) supplementation (control group) in GnRH antagonist or microdose GnRH agonist protocols
Number of subjects: 166
Study: 16533095

Group type: EXPERIMENTAL
Intervention: 8-week, one-on-one book-sharing intervention with twice-weekly 15-min sessions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 30
Study: 14700441

Group type: EXPERIMENTAL
Intervention: 1% topical pimecrolimus cream
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11261480

Group type: EXPERIMENTAL
Intervention: Day 2 embryo transfer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Day 5 embryo transfer
Number of subjects: 0
Study: 9168369

Group type: EXPERIMENTAL
Intervention: Small-peptide enteral diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Whole-protein diet
Number of subjects: 50
Study: 7967299

Group type: EXPERIMENTAL
Intervention: Endoscopic trigonoplasty
Number of subjects: 12

Group type: COMPARATOR
Intervention: Open trigonoplasty
Number of subjects: 12
Study: 3121233

Group type: EXPERIMENTAL
Intervention: Radiotherapy and methotrexate
Number of subjects: 313

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 313
Study: 29766750

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus Aspirin
Number of subjects: 4881

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 4881
Study: 27389963

Group type: EXPERIMENTAL
Intervention: Basic periodontal therapy + 0.12% chlorhexidine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Basic periodontal therapy + placebo
Number of subjects: 37
Study: 26050790

Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance exercise (n = 102)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual care (n = 102)
Number of subjects: 204
Study: 23040413

Group type: EXPERIMENTAL
Intervention: L-arginine-enriched biscuits
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo biscuits
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Powdered L-arginine
Number of subjects: 15
Study: 21569473

Group type: EXPERIMENTAL
Intervention: 4 l/min of oxygen from a simple face mask
Number of subjects: 34

Group type: COMPARATOR
Intervention: 4 l/min air from a face mask
Number of subjects: 34

Group type: COMPARATOR
Intervention: Air from a fan
Number of subjects: 34

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 34
Study: 19351690

Group type: EXPERIMENTAL
Intervention: Verapamil-SR
Number of subjects: 22576

Group type: COMPARATOR
Intervention: Atenolol-based strategies
Number of subjects: 22576

Group type: EXPERIMENTAL
Intervention: Follow-up PP as a continuous variable
Number of subjects: 22576

Group type: EXPERIMENTAL
Intervention: Follow-up SBP, DBP, MAP
Number of subjects: 22576
Study: 16957557

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg once/day
Number of subjects: 11

Group type: COMPARATOR
Intervention: Celecoxib 400 mg once/day
Number of subjects: 11
Study: 15002657

Group type: EXPERIMENTAL
Intervention: Gluconolactone-containing products (PHAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycolic acid-containing products (AHAs)
Number of subjects: 0
Study: 11110735

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg once daily
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Combination treatment (Candesartan + Lisinopril)
Number of subjects: 199
Study: 9066184

Group type: EXPERIMENTAL
Intervention: Oxatomide (1 to 2 mg/kg body weight, twice daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 64
Study: 8332009

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 70
Study: 3089465

Group type: EXPERIMENTAL
Intervention: Adenosine (maximum tolerable dose ranging from 10.6 to 37.1 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aminophylline 5 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dipyridamole 10 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study: 29722619

Group type: EXPERIMENTAL
Intervention: Whole body vibration training (WBVT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study: 26750674

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 47

Group type: COMPARATOR
Intervention: Nitroglycerine (NTG)
Number of subjects: 47
Study: 25210909

Group type: EXPERIMENTAL
Intervention: FHP intervention (n=12 health centers)
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: HCC intervention (n=9 health centers)
Number of subjects: 918

Group type: COMPARATOR
Intervention: HCC control group (n=11 health centers)
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: FHP intervention
Number of subjects: 918
Study: 22870960

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 5.1J (60J/cm²) energy density, applied at three different points intraorally immediately and at 48 and 72 hours post-surgery
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo group (laser device applied without activation)
Number of subjects: 14
Study: 20046173

Group type: EXPERIMENTAL
Intervention: Ketamine (1.5 mg/kg) and Diazepam (0.1 mg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Midazolam (0.05 mg/kg) and Fentanyl (1 microg/kg)
Number of subjects: 120
Study: 18371114

Group type: EXPERIMENTAL
Intervention: Thalidomide (THAL) arm of TT2
Number of subjects: 899

Group type: COMPARATOR
Intervention: Total therapy 1 (TT1)
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Total therapy 2 (TT2) without THAL
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Total therapy 2 (TT2)
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Total therapy 2 (TT2) without cytogenetic abnormalities (CA)
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Total therapy 2 (TT2) with cytogenetic abnormalities (CA)
Number of subjects: 899
Study: 16236670

Group type: EXPERIMENTAL
Intervention: National all farm index (AFI) ratio
Number of subjects: 2360

Group type: COMPARATOR
Intervention: National fuel index
Number of subjects: 2360

Group type: COMPARATOR
Intervention: Regional milk prices
Number of subjects: 2360
Study: 12879828

Group type: EXPERIMENTAL
Intervention: Prioritized review criteria for angina
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Prioritized review criteria plus feedback for angina
Number of subjects: 81

Group type: COMPARATOR
Intervention: Full guidelines for asthma
Number of subjects: 81

Group type: COMPARATOR
Intervention: Reduced guidelines for asthma
Number of subjects: 81

Group type: COMPARATOR
Intervention: Prioritized review criteria for asthma
Number of subjects: 81

Group type: COMPARATOR
Intervention: Prioritized review criteria plus feedback for asthma
Number of subjects: 81
Study: 10901965

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (ART) - 59.4 Gy in 33 fractions over 24 days
Number of subjects: 320

Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT) - 70 Gy in 35 fractions over 49 days
Number of subjects: 320
Study: 8666709

Group type: EXPERIMENTAL
Intervention: Depressed participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study: 8227859

Group type: EXPERIMENTAL
Intervention: Bradykinin (0.5, 5, and 50 nmol)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Kallidin (0.5, 5, and 50 nmol)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: [desArg9]-bradykinin (50 nmol)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Terfenadine (antihistamine)
Number of subjects: 16
Study: 3897335

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic antibiotics
Number of subjects: 0
Study: 30370830

Group type: EXPERIMENTAL
Intervention: Daily oral and vaginal tenofovir formulations for HIV prevention
Number of subjects: 322
Study: 27159248

Group type: EXPERIMENTAL
Intervention: Conjunctival impression cytology (CIC) specimens from exposed nasal bulbar conjunctiva
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Conjunctival impression cytology (CIC) specimens including fields without goblet cells
Number of subjects: 22
Study: 24319038

Group type: EXPERIMENTAL
Intervention: Epidural motor cortex stimulation (MCS)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (off-stimulation)
Number of subjects: 5
Study: 21613384

Group type: EXPERIMENTAL
Intervention: A1298/A1298 major allele homozygosity
Number of subjects: 2154

Group type: EXPERIMENTAL
Intervention: A1298/A1298 homozygotes
Number of subjects: 2154

Group type: EXPERIMENTAL
Intervention: C677T haplotype analysis
Number of subjects: 2154
Study: 20642705

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 3000
Study: 18327092

Group type: EXPERIMENTAL
Intervention: 'in‐treatment' segmental wall motion abnormalities
Number of subjects: 749
Study: 15796632

Group type: EXPERIMENTAL
Intervention: Coping skills training (CST)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 12-step facilitation (TSF)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Delayed treatment (DTC)
Number of subjects: 171
Study: 11910258

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 284

Group type: COMPARATOR
Intervention: Fluoxetine, Sertraline, Paroxetine
Number of subjects: 284
Study: 10485776

Group type: COMPARATOR
Intervention: Sevoflurane 2.0% with 0% nitrous oxide
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sevoflurane 2.5% with 33% nitrous oxide
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sevoflurane 3.0% with 66% nitrous oxide
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sevoflurane 3.5% with 0% nitrous oxide
Number of subjects: 72
Study: 8842861

Group type: EXPERIMENTAL
Intervention: Fasting or purging (reported by 23% of participants, n = 205)
Number of subjects: 886

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 886
Study: 1908604

Group type: EXPERIMENTAL
Intervention: Almitrine 100 mg twice a day reducing to 50 mg twice a day over 48 hours
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 6150839

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg and 10 mg doses per 24 hours
Number of subjects: 10
Study: 31550820

Group type: EXPERIMENTAL
Intervention: Real world study (RWS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnostic test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prognostic research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictive research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacoeconomic data
Number of subjects: 0
Study: 30413199

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing intrauterine contraceptive device (LNG IUD)
Number of subjects: 1860
Study: 26415520

Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement program (three individualized in-hospital education sessions and three weekly sessions of telephone counseling)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement program
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (supervised exercise and activities of daily living performance regimen, education)
Number of subjects: 66
Study: 24823959

Group type: EXPERIMENTAL
Intervention: Exergame training (playing exergames on an unstable platform)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional balance training (control)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Single-task (ST) exercises on the unstable platform
Number of subjects: 61
Study: 22741167

Group type: EXPERIMENTAL
Intervention: Regular salad dressing as a dip
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Light (reduced energy/fat) dressing as a dip
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Mixed with regular dressing as a sauce
Number of subjects: 152

Group type: COMPARATOR
Intervention: Plain (without dressing)
Number of subjects: 152
Study: 22254048

Group type: EXPERIMENTAL
Intervention: Prebiotic supplementation (mixture of long‐chain fructo‐oligosaccharides, galacto‐oligosaccharides, and acidic oligosaccharides)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Prebiotic supplementation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control (non-supplemented)
Number of subjects: 104
Study: 18277519

Group type: EXPERIMENTAL
Intervention: Antecedent stimuli in different modalities (national anthems, stories, architectural objects, paintings)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Experience of thrills from music (Rachmaninoff and Haydn)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Priming stimuli
Number of subjects: 223

Group type: COMPARATOR
Intervention: Altruism, self-concept, and mood measures
Number of subjects: 223
Study: 16137275

Group type: EXPERIMENTAL
Intervention: Daily multidisciplinary geriatric intervention (n=155)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Usual care (n=164)
Number of subjects: 319
Study: 12177585

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Haloperidol (3-15 mg/day)
Number of subjects: 453
Study: 9528165

Group type: EXPERIMENTAL
Intervention: D + O (Dextromethorphan + Oxatomide)
Number of subjects: 20

Group type: COMPARATOR
Intervention: D (Dextromethorphan)
Number of subjects: 20
Study: 7629335

Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement (GIC) restorations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Composite restorations
Number of subjects: 0
Study: 2146863

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF; 3 pmol/kg/min; 10 ng/kg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 323525

Group type: EXPERIMENTAL
Intervention: Propranolol plus hydrochlorothiazide (P+T)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Propranolol plus hydrochlorothiazide plus hydralazine (P+T+H)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Reserpine plus hydrochlorothiazide (R+T)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Propranolol plus hydralazine (P+H)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Propranolol alone (P)
Number of subjects: 450
Study: 31549622

Group type: EXPERIMENTAL
Intervention: Bespoke smoking cessation (BSC) intervention delivered by mental health specialists trained to deliver evidence‐supported smoking cessation interventions
Number of subjects: 526

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: BSC intervention
Number of subjects: 526
Study: 28605159

Group type: EXPERIMENTAL
Intervention: 6-month weight loss intervention
Number of subjects: 0
Study: 26031313

Group type: EXPERIMENTAL
Intervention: Mailed personalized feedback intervention regarding alcohol consumption
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 286
Study: 23818227

Group type: EXPERIMENTAL
Intervention: Cirrus OCT
Number of subjects: 42

Group type: COMPARATOR
Intervention: GDx-VCC
Number of subjects: 42
Study: 21805462

Group type: EXPERIMENTAL
Intervention: Pedometer group (education and encouraged to obtain 10,000 steps per day)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual Lifestyle group (no change in activity advised)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study: 20008235

Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Escalated BEACOPP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASCT (autologous stem cell transplantation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-ASCT strategies (salvage radiotherapy or non-ASCT chemotherapy)
Number of subjects: 0
Study: 17464688

Group type: EXPERIMENTAL
Intervention: Computerized cognitive behavioural therapy (CCBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 15675207

Group type: EXPERIMENTAL
Intervention: 4 ml 1% lignocaine pre‐treatment followed by propofol and 2 ml saline
Number of subjects: 100

Group type: COMPARATOR
Intervention: 4 ml saline followed by propofol and 2 ml 2% lignocaine
Number of subjects: 100
Study: 11704028

Group type: EXPERIMENTAL
Intervention: High-dose vitamin and mineral supplements
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1230
Study: 9042042

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey formula with Lactobacillus GG (5 x 10(8) colony-forming units/gm formula)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey formula with Lactobacillus GG
Number of subjects: 27

Group type: COMPARATOR
Intervention: Extensively hydrolyzed whey formula without Lactobacillus GG
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups (with and without Lactobacillus GG)
Number of subjects: 27
Study: 7699575

Group type: EXPERIMENTAL
Intervention: Pectin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2853459

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg once daily)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Unfractionated heparin (5,000 units every 8 hours)
Number of subjects: 237
Study: 30516625

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA) 50 mg/kg loading dose and 10 mg/kg/h infusion
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 27671885

Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Number of subjects: 43

Group type: COMPARATOR
Intervention: General Anesthesia
Number of subjects: 43
Study: 25609939

Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors (AChEIs)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Concurrent medications considered strong or moderate inhibitors of CYP2D6
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Concurrent medications considered strong or moderate inhibitors of CYP3A4/5
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CYP2D6 activity score
Number of subjects: 105
Study: 23025837

Group type: EXPERIMENTAL
Intervention: brotizolam
Number of subjects: 253

Group type: COMPARATOR
Intervention: estazolam
Number of subjects: 253
Study: 20873909

Group type: EXPERIMENTAL
Intervention: CCAL (computer-assisted cognitive behavioral therapy)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ICBT (individual cognitive behavioral therapy)
Number of subjects: 49

Group type: COMPARATOR
Intervention: CESA (computer-assisted education, support, and attention)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CCAL and ICBT
Number of subjects: 49
Study: 19102419

Group type: COMPARATOR
Intervention: Sitting position (control group)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lying position
Number of subjects: 10
Study: 16637791

Group type: EXPERIMENTAL
Intervention: Electronic tool with monitoring guidelines developed by physicians and pharmacists
Number of subjects: 9139

Group type: COMPARATOR
Intervention: Usual-care (control)
Number of subjects: 9139

Group type: EXPERIMENTAL
Intervention: Electronic tool for amiodarone monitoring
Number of subjects: 9139

Group type: EXPERIMENTAL
Intervention: Electronic tool for theophylline monitoring
Number of subjects: 9139

Group type: EXPERIMENTAL
Intervention: Electronic tool for carbamazepine monitoring
Number of subjects: 9139

Group type: EXPERIMENTAL
Intervention: Electronic tool for lithium monitoring
Number of subjects: 9139

Group type: EXPERIMENTAL
Intervention: Electronic tool for phenytoin monitoring
Number of subjects: 9139

Group type: EXPERIMENTAL
Intervention: Electronic tool for metformin monitoring
Number of subjects: 9139

Group type: EXPERIMENTAL
Intervention: Laboratory tests ordered
Number of subjects: 9139
Study: 12786953

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoride dentifrice
Number of subjects: 0
Study: 11004356

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 8646249

Group type: EXPERIMENTAL
Intervention: Triglyceride-heparin infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study: 1282182

Group type: EXPERIMENTAL
Intervention: Nicorandil (30 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 6518296

Group type: EXPERIMENTAL
Intervention: Radionuclide scans every six months for the first three postoperative years and yearly thereafter.
Number of subjects: 2697

Group type: EXPERIMENTAL
Intervention: Routine bone scans
Number of subjects: 2697

Group type: EXPERIMENTAL
Intervention: Yearly scans for asymptomatic patients with positive axillary nodes
Number of subjects: 2697
Study: 29274034

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (COL) 20 g/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 31
Study: 29566746

Group type: EXPERIMENTAL
Intervention: Activity tracker
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Activity tracker plus incentive groups
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 800
Study: 26931491

Group type: EXPERIMENTAL
Intervention: HAPPY intervention (6 antenatal, 6 postnatal sessions), N=59
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care, N=61
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HAPPY intervention
Number of subjects: 120